Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Site Search
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
Managing cystic fibrosis can feel overwhelming at times — but we’re here to help. Learn how to navigate life with CF.
Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.
Active cycle of breathing technique (ACBT) combines different breathing techniques that help clear mucus from the lungs in three phases. The first phase helps you relax your airways. The second phase helps you to get air behind mucus and clears mucus. The third phase helps force the mucus out of your lungs.
There are different ways to clear your airways. Most are easy to do. Infants and toddlers will need help from a parent or caregiver. Older kids and adults can choose airway clearance techniques (ACTs) that they can do on their own.
Although cystic fibrosis affects many parts of the body, the focus is often on the lungs because of the disease's effect on breathing.
Autogenic drainage (AD) means “self-drainage” and uses different speeds of breathing to move mucus. To do it, your respiratory therapist can teach you how to control your breaths. You will learn how fast and deeply to breathe to fill certain parts of your lungs with air. AD can take some practice and is usually recommended for people age 8 and older.